Seattle, WASHINGTON15 Active Studies

Ankylosing Spondylitis Clinical Trials in Seattle, WASHINGTON

Find 15 actively recruiting ankylosing spondylitis clinical trials in Seattle, WASHINGTON. Connect with local research sites and explore new treatment options.

15
Active Trials
12
Sponsors
1,410
Enrolling

Recruiting Ankylosing Spondylitis Studies in Seattle

RecruitingSeattle, WASHINGTONNCT04521231

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leu...

281 participants
Amgen
View Study Details
RecruitingSeattle, WASHINGTONNCT04422652

Combination of Novel Therapies for CKD Comorbid Depression

The overall goal of the study is to determine if treatment of a Major Depressive Disorder (MDD) improves the outcomes of patients with chronic kidney disease (CKD). We showed that MDD is present in 25...

201 participants
Stony Brook University
View Study Details
RecruitingSeattle, WASHINGTONNCT05765812

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiothera...

116 participants
Debiopharm International SA
View Study Details
RecruitingSeattle, WASHINGTONNCT05776069

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand...

116 participants
Vega Therapeutics, Inc
View Study Details
RecruitingSeattle, WASHINGTONNCT02323399

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

100 participants
West-Ward Pharmaceutical
View Study Details
RecruitingSeattle, WASHINGTONNCT04841148

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor dissemin...

96 participants
Abramson Cancer Center at Penn Medicine
View Study Details
RecruitingSeattle, WASHINGTONNCT05996627

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem ...

82 participants
Fred Hutchinson Cancer Center
View Study Details
RecruitingSeattle, WASHINGTONNCT06782373

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

This study is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestati...

78 participants
Swedish Orphan Biovitrum
View Study Details
RecruitingSeattle, WASHINGTONNCT06384573

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to...

65 participants
Washington University School of Medicine
View Study Details
RecruitingSeattle, WASHINGTONNCT05822609

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and s...

60 participants
University of Washington
View Study Details
RecruitingSeattle, WASHINGTONNCT05772546

Avatrombopag vs. Placebo for CIT in GI Malignancies

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (...

60 participants
Hanny Al-Samkari, MD
View Study Details
RecruitingSeattle, WASHINGTONNCT06179303

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib i...

60 participants
University of Washington
View Study Details
RecruitingSeattle, WASHINGTONNCT07011810

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell trans...

50 participants
Fred Hutchinson Cancer Center
View Study Details
RecruitingSeattle, WASHINGTONNCT05455658

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system ...

33 participants
University of Washington
View Study Details
RecruitingSeattle, WASHINGTONNCT06353997

Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is being evaluated to provide an informal comparison of p...

12 participants
Providence Health & Services
View Study Details

About Ankylosing Spondylitis Clinical Trials in Seattle

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 15 ankylosing spondylitis clinical trials recruiting participants in Seattle, WASHINGTON. These studies are seeking a combined 1,410 participants. Research is being sponsored by Amgen, Stony Brook University, Debiopharm International SA and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Seattle — FAQ

Are there ankylosing spondylitis clinical trials in Seattle?

Yes, there are 15 ankylosing spondylitis clinical trials currently recruiting in Seattle, WASHINGTON. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Seattle?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Seattle research site will contact you about next steps.

Are clinical trials in Seattle free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Seattle studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 15 active trials in Seattle are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated March 2, 2026 from ClinicalTrials.gov